Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.

Terui S, Akamatsu R, Arai M, Inoue R, Okuyama T, Kyohara M, Li J, Tsuno T, Miyashita D, Togashi Y, Terauchi Y, Shirakawa J

Diabetes therapy : research, treatment and education of diabetes and related disorders17 Sept 2021Cited by 3 (Europe PMC)

PMID34533697PMCIDPMC8519979DOI10.1007/s13300-021-01147-2PepBankPUB-34533697

Read at source PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In hospitalized patients with type 2 diabetes, dulaglutide was linked to reduced fasting glucose versus baseline, maintained for 5 days.
In plain wordsDulaglutide was linked to lower fasting blood sugar than baseline in hospitalized patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting blood glucose
Study
n = 80
Comparator
Baseline (day -1)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mgAs given in this study (human).
Source sentences
Summary
Significant reduction of the fasting BG, preprandial BG, postprandial BG, and standard deviation (SD) of the 6-point BG levels was observed on day 1 as compared to day - 1 (P < 0.0001) and the reduced BG levels were maintained throughout the remaining observation period of 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
Report a problemFND-3453369701
02HumanObservational studyEfficacy outcome
In hospitalized patients with diabetes, dulaglutide was linked to reduced preprandial glucose versus baseline, maintained for 5 days.
In plain wordsDulaglutide was linked to lower blood sugar before meals than baseline in hospitalized patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePreprandial blood glucose
Study
n = 80
Comparator
Baseline (day -1)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mgAs given in this study (human).
Source sentences
Summary
Significant reduction of the fasting BG, preprandial BG, postprandial BG, and standard deviation (SD) of the 6-point BG levels was observed on day 1 as compared to day - 1 (P < 0.0001) and the reduced BG levels were maintained throughout the remaining observation period of 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
Report a problemFND-3453369702
03HumanObservational studyEfficacy outcome
In hospitalized patients with diabetes, dulaglutide was linked to reduced postprandial glucose versus baseline, maintained for 5 days.
In plain wordsDulaglutide was linked to lower blood sugar after meals than baseline in hospitalized patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial blood glucose
Study
n = 80
Comparator
Baseline (day -1)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mgAs given in this study (human).
Source sentences
Summary
Significant reduction of the fasting BG, preprandial BG, postprandial BG, and standard deviation (SD) of the 6-point BG levels was observed on day 1 as compared to day - 1 (P < 0.0001) and the reduced BG levels were maintained throughout the remaining observation period of 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
Report a problemFND-3453369703
04HumanObservational studyEfficacy outcome
In hospitalized patients with diabetes, glucose standard deviation decreased on the day after dulaglutide versus baseline.
In plain wordsDulaglutide was linked to less blood sugar variation than baseline in hospitalized patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBlood glucose standard deviation
Study
n = 80
Comparator
Baseline (day -1)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mgAs given in this study (human).
Source sentences
Summary
Significant reduction of the fasting BG, preprandial BG, postprandial BG, and standard deviation (SD) of the 6-point BG levels was observed on day 1 as compared to day - 1 (P < 0.0001) and the reduced BG levels were maintained throughout the remaining observation period of 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
Report a problemFND-3453369704
05HumanObservational studyEfficacy outcome
In hospitalized patients with diabetes, dulaglutide was linked to glucose reduction irrespective of previous antidiabetic drug class.
In plain wordsDulaglutide was linked to lower blood sugar regardless of prior diabetes drug class in hospitalized patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGlucose reduction across previous medications
Study
n = 80
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mgAs given in this study (human).
Source sentences
Summary
Dulaglutide reduced the BG levels, irrespective of the previously used class of antidiabetic medication(s).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
Report a problemFND-3453369712

Studies that did not test the peptide alone7

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, higher baseline HbA1c was linked to greater fasting glucose reduction after dulaglutide.
In plain wordsHigher initial HbA1c was linked to greater fasting blood sugar reduction after dulaglutide in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBaseline HbA1c response association
Study
n = 80
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The baseline serum hemoglobin A1c and glycoalbumin levels were positively correlated with the reduction of the fasting BG.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369705
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, higher baseline glycoalbumin was linked to greater fasting glucose reduction after dulaglutide.
In plain wordsHigher initial glycoalbumin was linked to greater fasting blood sugar reduction after dulaglutide in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBaseline glycoalbumin response association
Study
n = 80
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The baseline serum hemoglobin A1c and glycoalbumin levels were positively correlated with the reduction of the fasting BG.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369706
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, glucose changes after dulaglutide were unrelated to insulin-secreting capacity.
In plain wordsInsulin-secreting capacity was not linked to blood sugar changes after dulaglutide in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeInsulin secretion response association
Study
n = 80
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The Δ BG levels were not related to the parameters of insulin-secreting capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369707
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, insulin treatment was linked to greater glucose reduction after dulaglutide.
In plain wordsInsulin treatment was linked to greater blood sugar reduction after dulaglutide in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseInsulin treatment response association
Study
n = 80
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin treatment was positively associated with the reduction of the 6-point BG levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369708
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, urinary microalbumin was positively linked to glucose improvement after dulaglutide.
In plain wordsHigher urine microalbumin was linked to greater blood sugar improvement after dulaglutide in patients with diabetes.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseMicroalbumin response association
Study
n = 80
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Urinary microalbumin level was positively correlated with improvements of the 6-point BG levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369711
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, absence of cerebrovascular disease was linked to greater fasting glucose improvement after dulaglutide.
In plain wordsPatients without cerebrovascular disease had greater fasting blood sugar improvement after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCerebrovascular disease response association
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Patients without cerebrovascular disease and patients without diabetic retinopathy showed greater improvements of the fasting BG and SD of the 6-point BG levels, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369709
12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In hospitalized patients with diabetes, absence of diabetic retinopathy was linked to greater improvement in glucose standard deviation after dulaglutide.
In plain wordsPatients without diabetic retinopathy had greater improvement in blood sugar variation after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseRetinopathy response association
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Patients without cerebrovascular disease and patients without diabetic retinopathy showed greater improvements of the fasting BG and SD of the 6-point BG levels, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting.
Summary · context
The changes (Δ) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day - 1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3453369710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.